Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and <i>in vivo</i> tumor growth in a highly tumorigenic ovarian cancer model.

Differently from D609-treated cells, for which significant 50%–60% decreases were confirmed in HER2 expression at 24–72 h (in agreement with data reported in Figure 3D ), cells exposed to TRTZ maintained a practically unaltered HER2 level up to 48 h ( P = 0.418) and showed only a borderline significant decrease to 60% at 72 h ( P = 0.066).

also in 11,409 other papers